[PRNewswire] Triastek announces research collaboration with Lilly to explore
the application of 3D printing technology in oral delivery of drugs
(NANJING, China, July 14, 2022 PRNewswire=연합뉴스) On July 13, 2022, Triastek, Inc. ("Triastek") announced a collaboration with Eli Lilly and Company ("Lilly"), a leading global pharmaceutical company, to leverage the advantages of 3D printing technology to enable precisely targeted and programmed release of drugs in specific regions of the GI tract.
According to the agreement, the project will focus on the targeted release of drugs in the intestine. Triastek will focus on two aspects: Firstly, conduct an in-depth study of excipient properties and process parameters to maintain drug stability throughout the formulation development and 3D printing process, as well as during drug release. Secondly, identify a unique three-dimensional structure dosage form design, that will permit programmed release of drugs in specific parts of the intestine, with the goal of improving the bioavailability of orally administered drugs.
Triastek is a 3D printing technology platform company, and its pioneering MED(R) technology has versatile applications in solid dosage forms development and manufacturing. With the facilitation of this collaboration by Lilly China Innovation & Partnerships, Triastek will work with Lilly to explore novel solutions to the oral delivery of drugs.
Triastek is committed to promoting the application of 3D printing technology in the pharmaceutical field. Triastek's 1st and 2nd products (T19 and T20) have received IND clearance from the U.S. Food and Drug Administration (FDA). The company also holds 158 patent applications related to 3D printing of pharmaceuticals with comprehensive patent coverage in the world. Triastek has also established collaborations with a number of multinational pharmaceutical companies, as well as domestic pharmaceutical companies to provide technical solutions for the development of challenging formulations.
Dr. Senping Cheng, founder and CEO of Triastek, said: "the collaboration between Triastek and Lilly is a great example of applying MED(R) technology for improving the oral delivery of drugs. We envision that the MED(R) technology of Triastek can be used to solve the challenges in formulations leading to the development of clinically valuable products for our global partners."
Triastek
Founded in 2015, Triastek, Inc. is the global leader in the 3D printing of pharmaceuticals and is pioneering the implementation of digital pharmaceutical solutions. Triastek's novel and proprietary 3D printing technology platform, encompasses dosage form design, digital pharmaceutical product development, and intelligent manufacturing.
Logo - https://mma.prnewswire.com/media/1550911/global_Logo.jpg
Logo (PRNewsfoto/Triastek, Inc.)
Source: Triastek, Inc.
[편집자주] 이 보도자료는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았으며, 연합뉴스의 편집방향과는 무관함을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
the application of 3D printing technology in oral delivery of drugs
(NANJING, China, July 14, 2022 PRNewswire=연합뉴스) On July 13, 2022, Triastek, Inc. ("Triastek") announced a collaboration with Eli Lilly and Company ("Lilly"), a leading global pharmaceutical company, to leverage the advantages of 3D printing technology to enable precisely targeted and programmed release of drugs in specific regions of the GI tract.
According to the agreement, the project will focus on the targeted release of drugs in the intestine. Triastek will focus on two aspects: Firstly, conduct an in-depth study of excipient properties and process parameters to maintain drug stability throughout the formulation development and 3D printing process, as well as during drug release. Secondly, identify a unique three-dimensional structure dosage form design, that will permit programmed release of drugs in specific parts of the intestine, with the goal of improving the bioavailability of orally administered drugs.
Triastek is a 3D printing technology platform company, and its pioneering MED(R) technology has versatile applications in solid dosage forms development and manufacturing. With the facilitation of this collaboration by Lilly China Innovation & Partnerships, Triastek will work with Lilly to explore novel solutions to the oral delivery of drugs.
Triastek is committed to promoting the application of 3D printing technology in the pharmaceutical field. Triastek's 1st and 2nd products (T19 and T20) have received IND clearance from the U.S. Food and Drug Administration (FDA). The company also holds 158 patent applications related to 3D printing of pharmaceuticals with comprehensive patent coverage in the world. Triastek has also established collaborations with a number of multinational pharmaceutical companies, as well as domestic pharmaceutical companies to provide technical solutions for the development of challenging formulations.
Dr. Senping Cheng, founder and CEO of Triastek, said: "the collaboration between Triastek and Lilly is a great example of applying MED(R) technology for improving the oral delivery of drugs. We envision that the MED(R) technology of Triastek can be used to solve the challenges in formulations leading to the development of clinically valuable products for our global partners."
Triastek
Founded in 2015, Triastek, Inc. is the global leader in the 3D printing of pharmaceuticals and is pioneering the implementation of digital pharmaceutical solutions. Triastek's novel and proprietary 3D printing technology platform, encompasses dosage form design, digital pharmaceutical product development, and intelligent manufacturing.
Logo - https://mma.prnewswire.com/media/1550911/global_Logo.jpg
Logo (PRNewsfoto/Triastek, Inc.)
Source: Triastek, Inc.
[편집자주] 이 보도자료는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았으며, 연합뉴스의 편집방향과는 무관함을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
